Guardant Health insider receives 264 vested shares

Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and settlement of equity awards.

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and settlement of equity awards. On August 21, 2026, 264 Restricted Stock Units were converted into 264 shares of Common Stock at $0.00 per share. Following these transactions, he holds 10,010 Common shares and 6,864 RSUs, all as direct ownership. The RSUs were from a November 8, 2024 grant that vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the next three years.

Insider Trade Summary

264 shares exercised/converted

Exercise 2 txns

Insider MIGNONE ROBERTO

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	264	$0.00	$0.00
Exercise	Common Stock	264	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 6,864 contracts (Direct); Common Stock — 10,010 shares (Direct)

Footnotes (2)

1. F1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

Key Figures

RSUs converted: 264 shares Conversion price per share: $0.00 Common Stock holdings after transaction: 10,010 shares +4 more

7 metrics

RSUs converted 264 shares Restricted Stock Units converted into Common Stock on August 21, 2026

Conversion price per share $0.00 RSU-to-Common Stock conversion on August 21, 2026

Common Stock holdings after transaction 10,010 shares Direct Common Stock owned by Roberto Mignone after August 21, 2026

RSU holdings after transaction 6,864 units Direct Restricted Stock Units remaining after August 21, 2026

RSU grant date November 8, 2024 Grant date of the RSU award that is vesting over four years

Initial cliff vesting percentage 25% Portion of RSU grant vesting on October 21, 2025

Remaining vesting period 3 years Remaining RSUs vest monthly over the three-year period after October 21, 2025

Key Terms

Restricted Stock Units, derivative security, vesting

3 terms

Restricted Stock Units financial

"The restricted stock unit award granted on November 8, 2024 vests over a four-year period."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Roberto Mignone report in this Form 4 for GH?

He reported the vesting and settlement of 264 Restricted Stock Units into 264 shares of Guardant Health Common Stock on August 21, 2026, at a conversion price of $0.00 per share, reflecting routine equity compensation mechanics rather than an open-market trade.

How many Guardant Health (GH) shares does Roberto Mignone own after this Form 4?

After the reported transactions, Roberto Mignone holds 10,010 shares of Common Stock directly and 6,864 Restricted Stock Units directly, as disclosed in the Form 4 totals following the August 21, 2026 equity award vesting and conversion.

What is the vesting schedule of Roberto Mignone’s RSU grant at Guardant Health (GH)?

The RSU award granted on November 8, 2024 vests over four years: 25% of the shares vested on October 21, 2025, and the remaining 75% vests monthly over the following three-year period, according to the Form 4 footnote.

Did Roberto Mignone buy or sell Guardant Health (GH) shares on the open market?

No. The Form 4 shows an exercise/conversion of 264 RSUs into 264 Common shares at $0.00 per share. There are no reported open-market purchase (P) or sale (S) transactions in this filing; it reflects equity award vesting.

Was Roberto Mignone’s Guardant Health (GH) transaction under a Rule 10b5-1 plan?

According to the filing’s 10b5-1 checkbox, the transactions were not affirmed as being made under a Rule 10b5-1 trading plan, as the document-level 10b5-1 indicator is marked false.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:21 PM EDT Accepted by SEC EDGAR 08/24/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGNONE ROBERTO

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		M		264	A	$0	10,010	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	08/21/2026		M			264	(1)	(2)	Common Stock	264	$0	6,864	D

Explanation of Responses:

1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Roberto A. Mignone	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)